# Model List of Essential Medicines

## Acetylsalicylic acid

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases<br>◦ Local > Rectal > Suppository: 150 mg; 300 mg<br>◦ Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg<br>◦ Oral > Solid > tablet: 75 to 500 mg | Mucocutaneous lymph node syndrome<br>Juvenile idiopathic arthritis<br>Acute rheumatic fever without mention of heart involvement |

## Adalimumab

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases<br>◦ Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL | Juvenile idiopathic arthritis |

## Allopurinol

| Section | Indications |
| --- | --- |
| Medicines used to treat gout<br>◦ Oral > Solid: 100 mg | Gout |

## Anakinra

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases<br>◦ Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe | Juvenile systemic arthritis |

## Azathioprine

| Section | Indications |
| --- | --- |
| Disease-modifying anti-rheumatic drugs (DMARDs)<br>◦ Oral > Solid > tablet: 50 mg (scored) | Rheumatoid arthritis, serology unspecified<br>Psoriatic arthritis |

## Certolizumab pegol

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases | Therapeutic equivalent to adalimumab for<br>Juvenile idiopathic arthritis |

## Chloroquine

| Section | Indications |
| --- | --- |
| Disease-modifying anti-rheumatic drugs (DMARDs)<br>◦ Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate) | Rheumatoid arthritis |

## Colchicine

| Section | Indications |
| --- | --- |
| Medicines used to treat gout<br>◦ Oral > Solid: 0.5 mg | Gout |

## Etanercept

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases | Therapeutic equivalent to adalimumab for<br>Juvenile idiopathic arthritis |

## Golimumab

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases | Therapeutic equivalent to adalimumab for<br>Juvenile idiopathic arthritis |

## Hydroxychloroquine

| Section | Indications |
| --- | --- |
| Disease-modifying anti-rheumatic drugs (DMARDs)<br>◦ Oral > Solid: 200 mg (as sulfate) | Systemic lupus erythematosus<br>Cutaneous lupus erythematosus of unspecified type |

## Infliximab

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases | Therapeutic equivalent to adalimumab for<br>Juvenile idiopathic arthritis |

## Methotrexate

| Section | Indications |
| --- | --- |
| Disease-modifying anti-rheumatic drugs (DMARDs)<br>◦ Oral > Solid > tablet: 2.5 mg (as sodium salt) | Rheumatoid arthritis, serology unspecified |
| Medicines for juvenile joint diseases<br>◦ Oral > Solid > tablet: 2.5 mg (as sodium salt) | Juvenile idiopathic arthritis |

## Penicillamine

| Section | Indications |
| --- | --- |
| Disease-modifying anti-rheumatic drugs (DMARDs)<br>◦ Oral > Solid: 250 mg | Rheumatoid arthritis, serology unspecified |

## Probenecid

| Section | Indications |
| --- | --- |
| Medicines used to treat gout<br>◦ Oral > Solid: 500 mg | Gout |

## Sulfasalazine

| Section | Indications |
| --- | --- |
| Disease-modifying anti-rheumatic drugs (DMARDs)<br>◦ Oral > Solid: 500 mg | Rheumatoid arthritis, serology unspecified |

## Tocilizumab

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases<br>◦ Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial<br>◦ Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe | Juvenile systemic arthritis |

## Triamcinolone hexacetonide

| Section | Indications |
| --- | --- |
| Medicines for juvenile joint diseases<br>◦ Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial | Juvenile idiopathic arthritis |